OR25-03 The Effects of Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, on Adrenal Androgens and Precursors in Patients with Classic Congenital Adrenal Hyperplasia: Resu...

por Auchus, Richard J, Sarafoglou, Kyriakie, Fechner, Patricia Y, Vogiatzi, Maria, Giri, Nagdeep, Roberts, Eiry, Sturgeon, Julia, Farber, Robert
Publicado 2020

OR18-4 Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, Lowers Adrenal Androgens and Precursors in Adolescents with Classic Congenital Adrenal Hyperplasia

por Auchus, Richard, Chan, Jean, Farber, Robert, Fechner, Patricia, Giri, Nagdeep, Nokoff, Natalie, Roberts, Eiry, Sarafoglou, Kyriakie, Sturgeon, Julia, Vogiatzi, Maria, Newfield, Ron
Publicado 2022

Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia

por Auchus, Richard J, Sarafoglou, Kyriakie, Fechner, Patricia Y, Vogiatzi, Maria G, Imel, Erik A, Davis, Shanlee M, Giri, Nagdeep, Sturgeon, Julia, Roberts, Eiry, Chan, Jean L, Farber, Robert H
Publicado 2021

Crinecerfont, a CRF(1) Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia

por Newfield, Ron S, Sarafoglou, Kyriakie, Fechner, Patricia Y, Nokoff, Natalie J, Auchus, Richard J, Vogiatzi, Maria G, Jeha, George S, Giri, Nagdeep, Roberts, Eiry, Sturgeon, Julia, Chan, Jean L, Farber, Robert H
Publicado 2023

Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial

por Christine, Chadwick W., Richardson, R. Mark, Van Laar, Amber D., Thompson, Marin E., Fine, Elisabeth M., Khwaja, Omar S., Li, Chunming, Liang, Grace S., Meier, Andreas, Roberts, Eiry W., Pfau, Madeline L., Rodman, Josh R., Bankiewicz, Krystof S., Larson, Paul S.
Publicado 2022